help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, H.
Right arrow Articles by Tuomi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, H.
Right arrow Articles by Tuomi, T.
The Journal of Clinical Endocrinology & Metabolism Vol. 88, No. 6 2767-2774
Copyright © 2003 by The Endocrine Society

A Combination of Human Leukocyte Antigen DQB1*02 and the Tumor Necrosis Factor {alpha} Promoter G308A Polymorphism Predisposes to an Insulin-Deficient Phenotype in Patients with Type 2 Diabetes

Haiyan Li, Leif Groop, Anita Nilsson, Jianping Weng and Tiinamaija Tuomi

Diabetes and Endocrine Research Laboratory (H.L., L.G., A.N., T.T.), Department of Endocrinology, Lund University, S-20502 Malmö, Sweden; Department of Endocrinology (J.W.), The First University Hospital, Sun Yat-Sen University, Guangzhou, China 510080; and Department of Internal Medicine (T.T.), Helsinki University Central Hospital, Helsinki FIN-00029, Finland

Address all correspondence and requests for reprints to: Haiyan Li, Ph.D., Wallenberg Laboratory, Department of Endocrinology, Lund University, S-20502 Malmö, Sweden. E-mail: haiyan.li{at}endo.mas.lu.se.

Our previous results have suggested that genes outside the human leukocyte antigen (HLA) class II locus may affect the phenotype of type 2 diabetic patients from families with both type 1 and type 2 diabetes (mixed type 1/2). To study whether the TNF{alpha} gene could be such a modifying gene, we studied TNF{alpha} promoter polymorphisms (G->A substitution at positions -308 and -238) in relation to HLA-DQB1 genotypes in type 2 patients from mixed type 1/2 families or common type 2 diabetes families as well as in patients with adult-onset type 1 diabetes and control subjects. The TNF{alpha}308 AA/AG genotype frequency was increased in adult onset type 1 patients (55%, 69 of 126), but it was similar in type 2 patients from type 1/2 families (35%, 33/93) or common type 2 families (31%, 122 of 395), compared with controls (33%, 95/284; P < 0.0001 vs. type 1). The TNF{alpha}308 A and DQB1*02 alleles were in linkage disequilibrium in type 1 patients (Ds = 0.81; P < 0.001 vs. Ds = 0.25 in controls) and type 2 patients from type 1/2 families (Ds = 0.59, P < 0.05 vs. controls) but not in common type 2 patients (Ds = 0.39). The polymorphism was associated with an insulin-deficient phenotype in the type 2 patients from type 1/2 families only together with DQB*02, whereas the common type 2 patients with AA/AG had lower waist to hip ratio [0.92 (0.12) vs. 0.94 (0.11), P = 0.008] and lower fasting C-peptide concentration [0.48 (0.47) vs. 0.62 (0.46) nmol/liter, P = 0.020] than those with GG, independently of the presence of DQB1*02. In conclusion, TNF{alpha} is unlikely to be the second gene in the HLA area responsible for our previous findings in type 1/2 patients. However, we could show an association between TNF{alpha}308 polymorphism and the phenotype of common type 2 diabetes.

This work was supported by the Sigrid Juselius Foundation, Påhlsson Foundation, Medical Faculty of the Lund University, Malmö University Hospital, Swedish National Board of Health and Welfare, Swedish Medical Doctors Association, Crafoord Foundation, and Novo Nordisk Foundation. The Botnia study is supported by the Sigrid Juselius Foundation, JDF Wallenberg, EC (BM4-CT95-0662), Swedish Medical Research Foundation, Academy of Finland, Finnish Diabetes Research Society, Swedish Diabetes Association, and Novo Nordisk Foundation.

Abbreviations: BMI, Body mass index; D, coefficient of disequilibrium; Ds, standardized value of D; HbA1C, hemoglobin A1C; HLA, human leukocyte antigen; HOMA, homeostasis model assessment for insulin resistance; OGTT, oral glucose tolerance test; GADab, glutamic acid decarboxylase antibody; WH, waist to hip ratio.




This article has been cited by other articles:


Home page
CVIHome page
A. A. Motala, M. Busson, E. M. Al-Harbi, M. A. A. Khuzam, E. M. D. Al-Omari, M. R. Arekat, and W. Y. Almawi
Susceptible and Protective Human Leukocyte Antigen Class II Alleles and Haplotypes in Bahraini Type 2 (Non-Insulin-Dependent) Diabetes Mellitus Patients
Clin. Vaccine Immunol., January 1, 2005; 12(1): 213 - 217.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2003 by The Endocrine Society